Press Releases

2023

Fr., 17.03.2023 - 15:53

argenx Announces Annual General Meeting of Shareholders on May 2, 2023

Mi., 15.03.2023 - 04:00

argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis

Do., 02.03.2023 - 00:54

argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update

Do., 02.03.2023 - 00:10

argenx Announces Planned Transition of Chief Operating Officer

Mo., 27.02.2023 - 15:25

argenx Appoints Steve Krognes to Board of Directors

Mo., 27.02.2023 - 16:06

argenx to Present at Upcoming Investor Conferences

Fr., 24.02.2023 - 06:42

argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023

Fr., 27.01.2023 - 01:14

argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod

Mo., 16.01.2023 - 13:18

argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director

Mo., 09.01.2023 - 00:58

argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline

Di., 03.01.2023 - 02:52

argenx to Present at 41st Annual J.P. Morgan Healthcare Conference

2022

Mo., 12.12.2022 - 05:05

argenx Appoints Ana Cespedes to Board of Directors